Evaluation of Cran-Max® for the Prevention
of UTI in Spinal Cord Injured Patients
with Neurogenic Bladders
Veteran Affairs,
Boston Healthcare System.
Design:
150 subjects; randomized, double-blind,
placebo controlled, crossover study,
2 years duration
Completed; awaiting statistical analysis
Preliminary Data
• Cran-Max® evaluated in over 100 patients
at dosage of 500 to 1000 mg once to
twice daily over 3 years
• Positive findings led to clinical review
of a sample of 12 patients
• UTI history and symptom questionnaire
• Urinalysis performed before and after
Cran-Max® usage (urinary pH, leucocyte
esterase and bacteriuria)
• Results: significant reduction in frequency
of UTI after the initiation of prophylaxis
• No significant change in urinary pH or the
incidence of leukocyte esterase
17